Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction

• Interferon beta-1b (Betaseron, BAY86-5046) (Drug): Applied via the BETACONNECT device. Dose as prescribed by physician.
• BETACONNECT device (Device): Used to apply Betaseron.

Primary outcomes

• Number of BETASERON injections as captured by the BETACONNECT device [At 6 months]
• Time (days) between BETASERON injections as captured by BETACONNECT device [At 6 months]

Secondary outcomes

• Patient reported satisfaction by a questionnaire [At 6 weeks]

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Male and females greater than or equal to 18 years of age
* Diagnosis of RRMS according to revised McDonald Criteria (2010) or (CIS)
* Prescribed BETASERON (note: decision to treat with BETASERON must be made independent of participation in this study)
* Confirmation of insurance coverage for BETASERON treatment
* Access to a personal computer to complete online patient satisfaction survey at Week 6

Exclusion Criteria:

* Currently enrolled in a clinical trial or other observational study for Multiple Sclerosis treatment
* Documented substance abuse within the previous 6 months prior to study enrollment
* Any major laboratory value abnormality that the investigator believes would preclude the patient from participating in the study
* Any medical disorder, condition or history that in the opinion of the investigator would impair the patient's ability to participate in or complete the study
* Pregnant or nursing

• Bayer Study Director, Study director, Bayer